



Pillar 3 Disclosure Report

31 March 2017

United Overseas Bank Limited
Incorporated in the Republic of Singapore



CONTENTS

Page

2	Introduction
3	Composition of Capital <ul style="list-style-type: none">- Reconciliation of Balance Sheet to Regulatory Capital- Capital Components- Key Features of Capital Instruments
10	Leverage Ratio <ul style="list-style-type: none">- Leverage Ratio- Reconciliation of Balance Sheet Assets to Exposure Measure- Exposure Measure Components
11	Risk Weighted Assets

INTRODUCTION

UOB Group's Pillar 3 Disclosure Report, prepared in accordance with the Monetary Authority of Singapore ("MAS") Notice to Banks No. 637 "Risk Based Capital Adequacy Requirements for Banks Incorporated in Singapore", comprises mandatory disclosures of the Group's capital composition, leverage ratio, and an overview of the Group's risk-weighted assets.

The Disclosure Report facilitates an assessment of the Group's capital adequacy and provides an overview of the Group's risk profile. For capital adequacy ratios of the Group's major bank subsidiaries, please refer to the Group Financial Report, available on UOB website www.UOBGroup.com/investor/financial/overview.html.

COMPOSITION OF CAPITAL

Tables 1 and 2 are mandatory disclosures under the MAS Notice 637 and Basel III transitional requirements presented in templates prescribed under MAS Notice 637.

Table 1 shows the reconciliation between the Group's published consolidated balance sheet and the regulatory capital components. Details of the regulatory capital components are set out in Table 2, as referenced.

The scope of consolidation for accounting and regulatory purposes is similar, except that subsidiaries which carry out insurance business are not consolidated for regulatory purpose. The list of the Group's major insurance subsidiaries can be found in the Group's Annual Report. As at 31 March 2017, total assets or total equities of each of these subsidiaries were less than S\$1 billion.

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 31 March 2017

S\$ million	Balance Sheet per Published Financial Statements	Under regulatory scope of consolidation	Reference in Table 2
Equity			
Share capital and other capital	6,353		
<i>of which paid-up ordinary shares</i>	4,258	4,258	A
<i>of which AT1 capital instruments</i>	2,094	2,094	B
Retained earnings	18,120	18,008	C
Other reserves	9,266	9,218	D
Equity attributable to equity holders of the Bank	33,739		
Non-controlling interests	175		
<i>of which transitional ineligible surplus NCI of bank subsidiaries</i>		0	E1
<i>of which NCI that meets criteria for inclusion in</i>			
- CET1 capital		13	E2
- AT1 capital		2	E3
- T2 capital		3	E4
Total equity	33,914		
Liabilities			
Deposits and balances of banks	11,227		
Deposits and balances of non-bank customers	259,672		
Bills and drafts payable	521		
Other liabilities	11,125		
Debts issued	26,115		
<i>of which transitional ineligible T2 capital instruments</i>	1,893	1,893	F1
<i>of which T2 capital instruments</i>	4,275	4,275	F2
Total liabilities	308,660		
Assets			
Cash, balances and placements with central banks	25,644		
Singapore Government treasury bills and securities	6,848		
Other government treasury bills and securities	10,222		
Trading securities	2,561		
Placements and balances with banks	42,849		
Loans to non-bank customers	225,107		
<i>of which provisions eligible for inclusion in T2 capital</i>		1,123	G
Investment securities ¹	11,113		
Other assets ¹	9,952		
<i>of which amount related to deferred tax assets (net of deferred tax liabilities, where permissible)</i>		308	H
Investment in associates and joint ventures ¹	1,145		
<i>of which amount related to goodwill</i>		7	I1
Investment properties	1,099		
Fixed assets	1,886		
Intangible assets	4,148		
<i>of which amount related to goodwill</i>		4,148	I2
Indirect investments in own capital instruments		1	J
Total Assets	342,574		

Abbreviations: (i) CET1 - Common Equity Tier 1; (ii) AT1 - Additional Tier 1; (iii) T2 - Tier 2

¹ Note: This includes the Bank's major stake investments in financial institutions.

COMPOSITION OF CAPITAL (cont'd)

Table 2 lists the regulatory capital components and the corresponding regulatory adjustments.

(a) 'Amount' refers to components of capital calculated in accordance with MAS Notice 637.

(b) 'Amount subject to Pre-Basel III Treatment' refers to components of capital that are computed on Basel III "transitional" rules.

(c) 'Reference in Table 1' links the respective line item to Table 1.

Regulatory adjustments that are deducted against capital are reflected as positive numbers. As the report is presented in S\$million, amounts less than \$500,000 are reflected as "0".

Table 2 - Capital Components as at 31 March 2017

	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Reference in Table 1
	Common Equity Tier 1 capital: instruments and reserves			
1	Paid-up ordinary shares and share premium (if applicable)	4,258		A
2	Retained earnings	18,008		C
3 [#]	Accumulated other comprehensive income and other disclosed reserves	9,218		D
4	Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies)	-		
5	Minority interest that meets criteria for inclusion	13	(0)	E1+E2, -E1
6	Common Equity Tier 1 capital before regulatory adjustments	31,497		
	Common Equity Tier 1 capital: regulatory adjustments			
7	Valuation adjustment pursuant to Part VIII of MAS Notice 637	-		
8	Goodwill, net of associated deferred tax liability	3,324	831	I1+I2
9 [#]	Intangible assets, net of associated deferred tax liability	-	-	
10 [#]	Deferred tax assets that rely on future profitability	246	62	H
11	Cash flow hedge reserve	-	-	
12	Shortfall of TEP relative to EL under IRBA	-	-	
13	Increase in equity capital resulting from securitisation transactions	-	-	
14	Unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk	-	-	
15	Defined benefit pension fund assets, net of associated deferred tax liability	-		
16	Investments in own shares	0		J
17	Reciprocal cross-holdings in ordinary shares of financial institutions	-		
18	Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank does not hold a major stake	-		
19	Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) (amount above 10% threshold)	-	-	
20 [#]	Mortgage servicing rights (amount above 10% threshold)	-		
21 [#]	Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability)	-		
22	Amount exceeding the 15% threshold	-		
23	<i>of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries)</i>	-		
24 [#]	<i>of which mortgage servicing rights</i>	-		
25 [#]	<i>of which deferred tax assets arising from temporary differences</i>	-		
26	National specific regulatory adjustments	-		
26A	PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	-	-	
26B	Capital deficits in subsidiaries and associates that are regulated financial institutions	-	-	
26C	Any other items which the Authority may specify	-		
27	Regulatory adjustments applied in calculation of CET1 Capital due to insufficient AT1 Capital to satisfy required deductions	-		
28	Total regulatory adjustments to CET1 Capital	3,570		
29	Common Equity Tier 1 capital (CET1)	27,927		
	Additional Tier 1 capital: instruments			
30	AT1 capital instruments and share premium (if applicable)	2,094		B
31	<i>of which classified as equity under the Accounting Standards</i>	2,094		
32	<i>of which classified as liabilities under the Accounting Standards</i>	-		
33	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	-		
34	AT1 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	2		E3
35	<i>of which instruments issued by subsidiaries subject to phase out</i>	-		
36	Additional Tier 1 capital before regulatory adjustments	2,096		
	Additional Tier 1 capital: regulatory adjustments			
37	Investments in own AT1 capital instruments	0		J

COMPOSITION OF CAPITAL (cont'd)
Table 2 - Capital Components as at 31 March 2017

	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Reference in Table 1
38	Reciprocal cross-holdings in AT1 capital instruments of financial institutions	-		
39	Investments in AT1 capital instruments of unconsolidated financial institutions in which Reporting Bank does not hold a major stake	-		
40	Investments in AT1 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries)	-	-	
41	National specific regulatory adjustments	892		
41A	Regulatory adjustments applied to AT1 Capital in respect of amounts subject to pre-Basel III treatment	892		
	<i>of which goodwill, net of associated deferred tax liability</i>	831		row 8 at 20%
	<i>of which intangible assets, net of associated deferred tax liability</i>	-		
	<i>of which deferred tax assets that rely on future profitability</i>	62		row 10 at 20%
	<i>of which cash flow hedge reserve</i>	-		
	<i>of which increase in equity capital resulting from securitisation transactions</i>	-		
	<i>of which unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk</i>	-		
	<i>of which shortfall of TEP relative to EL under IRBA</i>	-		
	<i>of which PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630</i>	-		
	<i>of which capital deficits in subsidiaries and associates that are regulated financial institutions</i>	-		
	<i>of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries)</i>	-		
	<i>of which investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries)</i>	-		
41B	Any other items which the Authority may specify	-		
42	Regulatory adjustments applied in calculation of AT1 Capital due to insufficient Tier 2 Capital to satisfy required deductions	-		
43	Total regulatory adjustments to Additional Tier 1 capital	892		
44	Additional Tier 1 capital (AT1)	1,204		
45	Tier 1 capital (T1 = CET1 + AT1)	29,131		
	Tier 2 capital: instruments and provisions			
46	Tier 2 capital instruments and share premium (if applicable)	4,275		F2
47	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	1,893		F1
48	Tier 2 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	3		E4
49	<i>of which instruments issued by subsidiaries subject to phase out</i>	-		
50	Provisions	1,123		G
51	Tier 2 capital before regulatory adjustments	7,293		
	Tier 2 capital: regulatory adjustments			
52	Investments in own Tier 2 instruments	0		J
53	Reciprocal cross-holdings in Tier 2 capital instruments of financial institutions	-		
54	Investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank does not hold a major stake	-		
55	Investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries)	-	-	
56	National specific regulatory adjustments	-		
56A	Any other items which the Authority may specify	-		
56B	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment	-		
	<i>of which shortfall of TEP relative to EL under IRBA</i>	-		
	<i>of which PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630</i>	-		
	<i>of which capital deficits in subsidiaries and associates that are regulated financial institutions</i>	-		
	<i>of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries)</i>	-		
	<i>of which investments in AT1 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries)</i>	-		
57	Total regulatory adjustments to Tier 2 capital	0		
58	Tier 2 capital (T2)	7,293		

COMPOSITION OF CAPITAL (cont'd)
Table 2 - Capital Components as at 31 March 2017

	S\$ million	Amount	Amount subject to Pre-BaseI III Treatment	Reference in Table 1
59	Total capital (TC = T1 + T2)	36,424		
60	Floor-adjusted total risk weighted assets (after incorporating the floor adjustment)	211,139		
	Capital ratios (as a percentage of floor-adjusted risk weighted assets)			
61	Common Equity Tier 1 CAR	13.2%		
62	Tier 1 CAR	13.8%		
63	Total CAR	17.3%		
64	Bank-specific buffer requirement	7.840%		
65	of which capital conservation buffer requirement	1.250%		
66	of which bank specific countercyclical buffer requirement ¹	0.090%		
67	of which G-SIB buffer requirement (if applicable)	-		
68	Common Equity Tier 1 available to meet buffers	5.8%		
	National minima			
69	Minimum CET1 CAR	6.5%		
70	Minimum Tier 1 CAR	8.0%		
71	Minimum Total CAR	10.0%		
	Amounts below the thresholds for deduction (before risk weighting)			
72	Investments in ordinary shares, AT1 capital and Tier 2 capital of unconsolidated financial institutions in which the bank does not hold a major stake	311		
73	Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries)	2,196		
74	Mortgage servicing rights (net of related tax liability)	-		
75	Deferred tax assets arising from temporary differences (net of related tax liability)	-		
	Applicable caps on the inclusion of provisions in Tier 2			
76	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach (prior to application of cap)	347		
77	Cap on inclusion of provisions in Tier 2 under standardised approach	284		row 50
78	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based approach (prior to application of cap)	1,043		
79	Cap for inclusion of provisions in Tier 2 under internal ratings-based approach	838		row 50
	Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2013 and 1 Jan 2022)			
80	Current cap on CET1 instruments subject to phase out arrangements	-		
81	Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)	-		
82	Current cap on AT1 instruments subject to phase out arrangements	1,074		
83	Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities)	-		
84	Current cap on T2 instruments subject to phase out arrangements	2,607		
85	Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)	-		

These elements are subject to a more conservative definition relative to those set out under the Basel III capital standards.

Note:

¹ The Group's countercyclical buffer (CCyB) is computed as the weighted average of effective CCyB in jurisdictions where the Group has private sector exposures. As at 31 Mar 2017, the Group has private sector exposures to Hong Kong and Sweden, where the effective country-specific CCyB was 1.250% for the year of 2017. The weights applied to Hong Kong and Sweden exposures are 7% and 0% respectively.

COMPOSITION OF CAPITAL (cont'd)

Key Features of Capital Instruments as at 31 March 2017

1	Issuer	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited
2	Unique Identifier (ISIN code)	SG1M31001969	SG72C9000002	SG58I7998534	SG57A1994579
3	Governing law(s) of the instrument	Singapore	Singapore	Singapore	Singapore
	Regulatory treatment				
4	Transitional Basel III rules	Core Equity	Additional Tier 1	Additional Tier 1	Additional Tier 1
5	Post-transitional Basel III rules	Core Equity	Additional Tier 1	Additional Tier 1	Additional Tier 1
6	Eligible at solo/group/group&solo	Group & Solo	Group & Solo	Group & Solo	Group & Solo
7	Instrument type	Ordinary Share	Perpetual Capital Security	Perpetual Capital Security	Perpetual Capital Security
8	Amount recognised in regulatory capital (in millions)	S\$4,258 million	S\$748 million	S\$499 million	S\$847 million
9	Principal amount (in millions)	n.a.	S\$750 million	S\$500 million	S\$850 million
10	Accounting classification	Equity	Equity	Equity	Equity
11	Original date of issuance	20 July 1970	18 May 2016	19 November 2013	23 July 2013
12	Perpetual or dated	Perpetual	Perpetual	Perpetual	Perpetual
13	Original maturity date	No maturity	No maturity	No maturity	No maturity
14	Issuer call subject to prior supervisory approval	n.a.	Yes	Yes	Yes
15	Optional call date	n.a.	18 May 2021	19 November 2019	23 July 2018
	Tax/ regulatory event call	n.a.	Yes	Yes	Yes
	Redemption price	n.a.	Par	Par	Par
16	Subsequent call dates, if applicable	n.a.	Each distribution payment date thereafter	Each distribution payment date thereafter	Each distribution payment date thereafter
	Coupons / dividends				
17	Fixed or floating ⁽¹⁾	Discretionary dividend amount	Fixed	Fixed	Fixed
18	Coupon rate and any related index	n.a.	4.00% paid semi-annually on 18 May & 18 November	4.75% paid semi-annually on 19 May & 19 November	4.90% paid semi-annually on 23 January & 23 July
19	Existence of a dividend stopper	n.a.	Yes	Yes	Yes
20	Fully discretionary, discretionally or mandatory	Fully discretionary	Fully discretionary	Fully discretionary	Fully discretionary
21	Existence of step up or incentive to redeem	n.a.	No	No	No
22	Non-cumulative or cumulative	Non-cumulative	Non-cumulative	Non-cumulative	Non-cumulative
23	Convertible or non-convertible	n.a.	Non-convertible	Non-convertible	Non-convertible
24	If convertible, conversion trigger	n.a.	n.a.	n.a.	n.a.
25	If convertible, fully or partially	n.a.	n.a.	n.a.	n.a.
26	If convertible, conversion rate	n.a.	n.a.	n.a.	n.a.
27	If convertible, mandatory or optional conversion	n.a.	n.a.	n.a.	n.a.
28	If convertible, specify instrument type convertible into	n.a.	n.a.	n.a.	n.a.
29	If convertible, specify issuer of instrument it converts into	n.a.	n.a.	n.a.	n.a.
30	Write-down feature	n.a.	Yes	Yes	Yes
31	If write-down, write-down triggers(s)	n.a.	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator
32	If write-down, full or partial	n.a.	Partial	Partial	Partial
33	If write-down, permanent or temporary	n.a.	Permanent	Permanent	Permanent
34	If temporary write-down, description of write-up mechanism	n.a.	n.a.	n.a.	n.a.
35	Position in subordination hierarchy in liquidation (instrument type immediately senior to instrument)	Additional Tier 1 instruments	Tier 2 instruments	Tier 2 instruments	Tier 2 instruments
36	Non compliant transitioned features	No	No	No	No
37	If yes, specify non compliant features	n.a.	n.a.	n.a.	n.a.

(1) Details on re-fixing of the dividend/interest rate on the first call date are available in the UOB website.

COMPOSITION OF CAPITAL (cont'd)
Key Features of Capital Instruments as at 31 March 2017

	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited
1 Issuer	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited
2 Unique Identifier (ISIN code)	SG79A8000002	XS1485603408	XS1480822516	XS1379133058
3 Governing law(s) of the instrument	Singapore	Singapore	Singapore	Singapore
Regulatory treatment				
4 Transitional Basel III rules	Tier 2	Tier 2	Tier 2	Tier 2
5 Post-transitional Basel III rules	Tier 2	Tier 2	Tier 2	Tier 2
6 Eligible at solo/group/group&solo	Group & Solo	Group & Solo	Group & Solo	Group & Solo
7 Instrument type	Subordinated Debt	Subordinated Debt	Subordinated Debt	Subordinated Debt
8 Amount recognised in regulatory capital (in millions)	S\$750 million	S\$830 million	S\$119 million	S\$957 million
9 Principal amount (in millions)	S\$750 million	US\$600 million	HK\$700 million	US\$700 million ⁽²⁾
10 Accounting classification	Liability	Liability	Liability	Liability
11 Original date of issuance	27 February 2017	8 September 2016	26 August 2016	16 & 24 March 2016
12 Perpetual or dated	Dated	Dated	Dated	Dated
13 Original maturity date	27 February 2029	8 March 2027	26 August 2028	16 September 2026
14 Issuer call subject to prior supervisory approval	Yes	Yes	Yes	Yes
15 Optional call date	27 February 2024	8 March 2022	26 August 2023	16 September 2021
Tax/ regulatory event call	Yes	Yes	Yes	Yes
Redemption price	Par	Par	Par	Par
16 Subsequent call dates, if applicable	Not applicable. One time call only.	Not applicable. One time call only.	Not applicable. One time call only.	Not applicable. One time call only.
Coupons / dividends				
17 Fixed or floating ⁽¹⁾	Fixed	Fixed	Fixed	Fixed
18 Coupon rate and any related index	3.50% paid semi-annually on 27 February and 27 August	2.88% paid semi-annually on 8 March and 8 September	3.19% paid quarterly on 26 August, 26 November, 26 February and 26 May	3.5% paid semi-annually on 16 March and 16 September
19 Existence of a dividend stopper	No	No	No	No
20 Fully discretionary, discretionally or mandatory	Mandatory	Mandatory	Mandatory	Mandatory
21 Existence of step up or incentive to redeem	No	No	No	No
22 Non-cumulative or cumulative	Cumulative	Cumulative	Cumulative	Cumulative
23 Convertible or non-convertible	Non-convertible	Non-convertible	Non-convertible	Non-convertible
24 If convertible, conversion trigger	n.a.	n.a.	n.a.	n.a.
25 If convertible, fully or partially	n.a.	n.a.	n.a.	n.a.
26 If convertible, conversion rate	n.a.	n.a.	n.a.	n.a.
27 If convertible, mandatory or optional conversion	n.a.	n.a.	n.a.	n.a.
28 If convertible, specify instrument type convertible into	n.a.	n.a.	n.a.	n.a.
29 If convertible, specify issuer of instrument it converts into	n.a.	n.a.	n.a.	n.a.
30 Write-down feature	Yes	Yes	Yes	Yes
31 If write-down, write-down triggers(s)	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator
32 If write-down, full or partial	Partial	Partial	Partial	Partial
33 If write-down, permanent or temporary	Permanent	Permanent	Permanent	Permanent
34 If temporary write-down, description of write-up mechanism	n.a.	n.a.	n.a.	n.a.
35 Position in subordination hierarchy in liquidation (instrument type immediately senior to instrument)	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations
36 Non compliant transitioned features	No	No	No	No
37 If yes, specify non compliant features	n.a.	n.a.	n.a.	n.a.

(2) US\$500m 3.5% subordinated notes were first issued on 16 March 2016. This was followed by a re-tap for US\$200m on 24 March 2016, which will be consolidated and form a single series with the US\$500m tranche issued on 16 March 2016.

COMPOSITION OF CAPITAL (cont'd)
Key Features of Capital Instruments as at 31 March 2017

1	Issuer	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited	United Overseas Bank Limited
2	Unique Identifier (ISIN code)	SG6QD3000002	XS1045409965	SG6V61983429	XS0843128603
3	Governing law(s) of the instrument	Singapore	Singapore	Singapore	Singapore
	Regulatory treatment				
4	Transitional Basel III rules	Tier 2	Tier 2	Tier 2	Tier 2
5	Post-transitional Basel III rules	Tier 2	Tier 2	Ineligible	Ineligible
6	Eligible at solo/group/group&solo	Group & Solo	Group & Solo	Group & Solo	Group & Solo
7	Instrument type	Subordinated Debt	Subordinated Debt	Subordinated Debt	Subordinated Debt
8	Amount recognised in regulatory capital (<i>in millions</i>)	S\$500 million	S\$1,119 million	S\$1,197 million	S\$696 million
9	Principal amount (<i>in millions</i>)	S\$500 million	US\$800 million	S\$1,200 million	US\$500 million
10	Accounting classification	Liability	Liability	Liability	Liability
11	Original date of issuance	22 May 2014	19 March 2014	11 July 2012	17 October 2012
12	Perpetual or dated	Dated	Dated	Dated	Dated
13	Original maturity date	22 May 2026	19 September 2024	11 July 2022	17 October 2022
14	Issuer call subject to prior supervisory approval	Yes	Yes	Yes	Yes
15	Optional call date	22 May 2020	19 September 2019	11 July 2017	17 October 2017
	Tax/ regulatory event call	Yes	Yes	Yes	Yes
	Redemption price	Par	Par	Par	Par
16	Subsequent call dates, if applicable	Not applicable. One time call only.	Not applicable. One time call only.	Each interest payment date thereafter	Each interest payment date thereafter
	Coupons / dividends				
17	Fixed or floating ⁽¹⁾	Fixed	Fixed	Fixed	Fixed
18	Coupon rate and any related index	3.5% paid semi-annually on 22 May and 22 November	3.75% paid semi-annually on 19 March and 19 September	3.15% paid semi-annually on 11 January and 11 July	2.875% paid semi-annually on 17 April and 17 October
19	Existence of a dividend stopper	No	No	No	No
20	Fully discretionary, discretionally or mandatory	Mandatory	Mandatory	Mandatory	Mandatory
21	Existence of step up or incentive to redeem	No	No	No	No
22	Non-cumulative or cumulative	Cumulative	Cumulative	Cumulative	Cumulative
23	Convertible or non-convertible	Non-convertible	Non-convertible	Non-convertible	Non-convertible
24	If convertible, conversion trigger	n.a.	n.a.	n.a.	n.a.
25	If convertible, fully or partially	n.a.	n.a.	n.a.	n.a.
26	If convertible, conversion rate	n.a.	n.a.	n.a.	n.a.
27	If convertible, mandatory or optional conversion	n.a.	n.a.	n.a.	n.a.
28	If convertible, specify instrument type convertible into	n.a.	n.a.	n.a.	n.a.
29	If convertible, specify issuer of instrument it converts into	n.a.	n.a.	n.a.	n.a.
30	Write-down feature	Yes	Yes	No	No
31	If write-down, write-down triggers(s)	Point of non-viability at the discretion of the Regulator	Point of non-viability at the discretion of the Regulator	n.a.	n.a.
32	If write-down, full or partial	Partial	Partial	n.a.	n.a.
33	If write-down, permanent or temporary	Permanent	Permanent	n.a.	n.a.
34	If temporary write-down, description of write-up mechanism	n.a.	n.a.	n.a.	n.a.
35	Position in subordination hierarchy in liquidation (<i>instrument type immediately senior to instrument</i>)	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations	Unsubordinated and unsecured obligations
36	Non compliant transitioned features	No	No	Yes	Yes
37	If yes, specify non compliant features	n.a.	n.a.	No loss absorption features	No loss absorption features

LEVERAGE RATIO

The Basel III framework introduced Leverage Ratio as a non-risk-based backstop limit to supplement the risk-based capital requirements. It aims to constrain the build-up of excess leverage in the banking sector, with additional safeguards against model risk and measurement errors.

Leverage Ratio is expressed as Tier 1 Capital against Exposure Measure, which comprises on- and off-balance sheet items.

S\$ million	Mar-17	Dec-16	Sep-16	Jun-16
Tier 1 capital	29,131	28,280	27,768	26,708
Exposure measure	384,439	380,238	367,848	361,877
Leverage ratio	7.6%	7.4%	7.5%	7.4%

Disclosure of Leverage Ratio is presented in prescribed templates under MAS Notice 637.

Table 1 shows the reconciliation between the Group's published balance sheet assets and the Exposure Measure.

Table 2 sets out the components of Exposure Measure.

Table 1 - Reconciliation of Balance Sheet Assets to Exposure Measure as at 31 March 2017

	S\$ million	Amount
1	Total consolidated assets as per published financial statements	342,574
2	Adjustment for investments in entities that are consolidated for accounting purposes but are outside the regulatory scope of consolidation	(574)
3	Adjustment for fiduciary assets recognised on the balance sheet in accordance with the Accounting Standards but excluded from the calculation of the exposure measure	-
4	Adjustment for derivative transactions	5,122
5	Adjustment for SFTs	106
6	Adjustment for off-balance sheet items	41,673
7	Other adjustments	(4,463)
8	Exposure measure	384,439

Table 2 - Exposure Measure Components as at 31 March 2017

	S\$ million	Amount
Exposure measures of on-balance sheet items		
1	On-balance sheet items (excluding derivative transactions and SFTs, but including on-balance sheet collateral for derivative transactions or SFTs)	328,118
2	Asset amounts deducted in determining Tier 1 capital	(4,463)
3	Total exposure measures of on-balance sheet items (excluding derivative transactions and SFTs)	323,655
Derivative exposure measures		
4	Replacement cost associated with all derivative transactions (net of the eligible cash portion of variation margins)	3,969
5	Potential future exposure associated with all derivative transactions	5,889
6	Gross-up for derivative collaterals provided where deducted from the balance sheet assets in accordance with the Accounting Standards	-
7	Deductions of receivables for the cash portion of variation margins provided in derivative transactions	-
8	CCP leg of trade exposures excluded	-
9	Adjusted effective notional amount of written credit derivatives	237
10	Further adjustments in effective notional amounts and deductions from potential future exposures of written credit derivatives	-
11	Total derivative exposure measures	10,095
SFT exposure measures		
12	Gross SFT assets (with no recognition of accounting netting), after adjusting for sales accounting	8,910
13	Eligible netting of cash payables and cash receivables	-
14	SFT counterparty exposures	106
15	SFT exposure measures where a Reporting Bank acts as an agent in the SFTs	-
16	Total SFT exposure measures	9,016
Exposure measures of off-balance sheet items		
17	Off-balance sheet items at notional amount	178,600
18	Adjustments for calculation of exposure measures of off-balance sheet items	(136,926)
19	Total exposure measures of off-balance sheet items	41,673
Capital and Total exposures		
20	Tier 1 capital	29,131
21	Total exposures	384,439
	Leverage ratio	
22	Leverage ratio	7.6%

RISK WEIGHTED ASSETS ("RWA")

The table below lists the Group's RWA by risk type and approach, as prescribed under MAS Notice 637 and the revised Pillar 3 disclosure requirements issued by Basel Committee in January 2015. The minimum capital requirement is stated at 10.0% of RWA.

The Group's RWA comprises credit RWA (84.6%), market RWA (9.0%), and operational RWA (6.4%).

Total RWA at 31 March 2017 was \$211.1 billion, or \$4.4 billion lower quarter-on-quarter, primarily due to enhancements in methodology for computation of market risk RWA effected in first quarter of 2017. Overall credit RWA was marginally lower, with improved credit quality partly offset by higher RWA from revisions in capital rules impacting equity exposures.

S\$ million		Risk Weighted Assets		Minimum Capital Requirement
		As at 31 Mar 2017 [#]	As at 31 Dec 2016	As at 31 Mar 2017
1	Credit risk (excluding CCR)	159,677	160,750	15,968
2	<i>of which SA(CR) and SA(EQ)</i>	21,166	20,926	2,117
3	<i>of which IRBA and IRBA(EQ) for equity exposures under the PD/LGD method</i>	138,510	139,824	13,851
4	CCR	5,528	6,467	553
5	<i>of which Current Exposure Method</i>	2,754	3,324	275
6	<i>of which CCR Internal Models Method</i>	-	-	-
7	IRBA(EQ) for equity exposures under the simple risk weight method or the IMM	4,566	5,096	457
8	Equity investments in funds - look through approach	252	-	25
9	Equity investments in funds - mandate-based approach	2,990	-	299
10	Equity investments in funds - fall back approach	14	-	1
10a	Equity investment in funds - partial use of an approach	-	-	-
11	Unsettled transactions	-	-	-
12	Securitisation exposures in the banking book	179	183	18
13	<i>of which IRBA(SE) - RBM and IAM</i>	179	183	18
14	<i>of which IRBA(SE) - SF</i>	-	-	-
15	<i>of which SA(SE)</i>	-	-	-
16	Market risk	19,026	23,138	1,903
17	<i>of which SA(MR)</i>	19,026	23,138	1,903
18	<i>of which IMA</i>	-	-	-
19	Operational risk	13,417	13,261	1,342
20	<i>of which BIA</i>	-	-	-
21	<i>of which SA(OR)</i>	13,417	13,261	1,342
22	<i>of which AMA</i>	-	-	-
23	Amounts below the thresholds for deduction - subject to 250% risk weight	5,490	6,664	549
24	Floor adjustment	-	-	-
25	Total	211,139	215,559	21,114

[#] In October 2016, revisions were made to the MAS Notice 637 to implement requirements that are consistent with the finalised Basel standards. Amendments which were effective from 1 January 2017 enhance the risk capture of banks' equity exposures and align the regulatory capital treatment of significant investments to the Basel framework.

Accordingly, these amendments impact RWA computation for equity exposures in major stake investments and investment in funds as at 31 March 2017, as reflected in rows 3, 7, 8 to 10a and 23 in the table above.